George Gemayel, Ph.D, has served as a member of our Board since 2015 and has served as consultant for several biotechnology companies and venture capital funds since 2010. From February 2011 to December 2012, Dr. Gemayel served as Executive Chairman of Syndexa Pharmaceuticals Corp., a privately held drug development company. In 2010, Dr. Gemayel served as Executive Chairman of FoldRx until its acquisition by Pfizer. From June 2008 until November 2009, Dr. Gemayel served as President and CEO of Altus Pharmaceuticals, a publicly traded pharmaceutical company. From 2003 to 2008, he was Executive Vice President at Genzyme Corporation, where he was responsible for Genzyme’s global therapeutics, transplant, renal and biosurgery business. From 2000 to 2003, Dr. Gemayel was employed as Vice President of National Specialty Care for Hoffmann La-Roche, responsible for its U.S. business for dermatology, oncology, transplantation, hepatitis, and HIV. Dr. Gemayel joined Hoffman La-Roche in 1988 and served in various positions of increasing responsibility over his tenure. Dr. Gemayel received his Doctorate in Pharmacy from Saint Joseph University in Beirut, Lebanon and his PhD in Pharmacology from Paris-Sud University in Paris, France. Dr. Gemayel currently serves as Chairman of the board of directors of Enterome Bioscience SA and GlycoEra AG (both privately held companies), as well as serving as a director of Disc Medicine Inc. and of Flamingo Therapeutics (both privately held companies). He was previously a Director of Adcolor Corporation, a publicly traded company acquired by Cubis Pharmaceuticals, Inc., a Director at Prosena, acquired by Biomarin, a Director at NPS, acquired by Shire, a Director of EpiTherapeutics, acquired by Gilead, and the Chairman of Vascular Magnetics, a privately owned company. Dr. Gemayel’s substantial experience on the Board of Directors of life science and healthcare companies and his over 25 years of experience in the pharmaceutical industry, including management and executive positions spanning the United States, Europe, and the Middle East, qualify him to serve as a director.
What is Georges Gemayel's net worth?
The estimated net worth of Georges Gemayel is at least $429,009.30 as of November 7th, 2024. Dr. Gemayel owns 13,315 shares of Supernus Pharmaceuticals stock worth more than $429,009 as of April 26th. This net worth evaluation does not reflect any other assets that Dr. Gemayel may own. Learn More about Georges Gemayel's net worth.
How do I contact Georges Gemayel?
The corporate mailing address for Dr. Gemayel and other Supernus Pharmaceuticals executives is 1550 E GUDE DR, ROCKVILLE MD, 20850. Supernus Pharmaceuticals can also be reached via phone at (301) 838-2500 and via email at gpatrick@supernus.com. Learn More on Georges Gemayel's contact information.
Has Georges Gemayel been buying or selling shares of Supernus Pharmaceuticals?
Georges Gemayel has not been actively trading shares of Supernus Pharmaceuticals during the last ninety days. Most recently, Georges Gemayel sold 14,213 shares of the business's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.62, for a transaction totalling $520,480.06. Following the completion of the sale, the director now directly owns 13,315 shares of the company's stock, valued at $487,595.30. Learn More on Georges Gemayel's trading history.
Who are Supernus Pharmaceuticals' active insiders?
Supernus Pharmaceuticals' insider roster includes Padmanabh Bhatt (Senior Vice President, Chief Scientific Officer, Intellectual Property), Georges Gemayel (Director), Frederick Hudson (Director), Jack Khattar (President and Chief Executive Officer, Director), Frank Mottola (SVP, GMP Operations, IT and Regulatory Affairs), and Jonathan Rubin (Senior Vice President, Chief Medical Officer, Research & Development). Learn More on Supernus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Supernus Pharmaceuticals?
In the last twelve months, insiders at the specialty pharmaceutical company sold shares 6 times. They sold a total of 165,317 shares worth more than $6,100,443.01. The most recent insider tranaction occured on February, 21st when SVP Jonathan Rubin sold 927 shares worth more than $36,292.05. Insiders at Supernus Pharmaceuticals own 9.3% of the company.
Learn More about insider trades at Supernus Pharmaceuticals. Information on this page was last updated on 2/21/2025.
